Phase II clinical trial - Appareil pulmonaire

Appareil pulmonaire
Ouvert depuis le: 04.20.2024
Site: Paris
Public cible
A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
Description de l'essai
Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer